 Patent Application Title |
Patent App Num. |
Date |
| Method and apparatus for classifying cardiac arrhythmia | 20130085405 | 20130404 |
 A method and a device for classifying cardiac arrhythmia, using an electrocardiogram (ECG) signal, are provided. The method includes receiving the ECG signal representing an electrical activity of a heart of an individual over a period of time, the ECG signal including ECG beats. The method further includes converting each of the ECG beats into symbols. The method further includes identifying an arrhythmia class indicating a type of cardiac arrhythmia associated with the individual from arrhythmia classes indicating respective types of cardiac arrhythmia based on the symbols representing each of the ECG beats.
... |
| Cardio mapping system and method for cardio mapping | 20130072774 | 20130321 |
 A method and system for determining the mechanism of cardiac arrhythmia in a patient is disclosed. The method basically entails measuring the impedance of cardiac tissue in a portion of the patient's heart using a catheter during an episode of supraventricular tachycardia to produce an iso-impedance map of that cardiac tissue on a video display and analyzing the pattern of the iso-impedance map to differentiate focal arrhythmia caused by a circumscribed region of focal firing and reentrant arrhythmia caused by a macroreentrant circuit. The method can also be used to identify regions of coherent rapidly conducting tissue e.g., Bachman's bundle or the inferoposterior pathway insertion points, to identify focal “mother rotors” throughout the left atrium that may participate in the generation and maintenance of atrial fibrillation... |
| System for cardiac arrhythmia detection and characterization | 20130072806 | 20130321 |
 A system for heart performance characterization and abnormality detection comprises an input processor and at least one signal processor. The input processor receives, sampled data representing a patient blood pressure signal and a concurrently acquired electrocardiogram (ECG) signal representing heart electrical activity of the patient. The at least one signal processor, synchronizes the patient blood pressure signal and the heart electrical activity signal, identifies at least two points of a heart electrical activity signal cycle, integrates signal data values representing the amplitude of the patient blood pressure signal of a segment between the identified two points to derive an integral value over time duration of the segment representing an area under the blood pressure signal waveform between the identified two points and in response to the... |
| Method and system for identifying cardiac arrhythmia driver sites | 20130066221 | 20130314 |
 A method of identifying potential driver sites for cardiac arrhythmias includes acquiring a plurality of electrograms from a plurality of locations on at least a portion of a patient's heart. Using the acquired electrograms, at least one electrical activity map is generated. Desirable electrical activity maps include complex fractionated electrogram standard deviation and mean maps, dominant frequency maps, peak-to-peak voltage maps, and activation sequence maps. Using one or more of these maps (e.g., by analyzing one or more electrogram morphological characteristics represented by these maps), at least one potential driver site can be detected.
... |
| Manipulation of calcium channels to regulate after-depolarization events in cardiac myocytes | 20130017198 | 20130117 |
 A novel mechanism by which after-depolarization occurs in cardiac myocytes has been discovered, involving calcium influx through the arachidonate-regulated calcium channel (ARCC) and the store-operated calcium channel (SOCC). Because after-depolarization of the myocyte is a major cause of cardiac arrhythmia, this discovery provides new approaches for treating and preventing heart disease. By down-regulating the activity of the ARCC or the SOCC, after-depolarization can be decreased and cardiac arrhythmia can be prevented, reduced, or eliminated. This can be accomplished using pharmaceuticals containing inhibitors of the ARCC or the SOCC, or by genetically modifying cells to reduce ARCC or SOCC activity. In addition, assays are disclosed using the ARCC or SOCC to discover potential anti-arrhythmic agents. Cellular and animal models of arrhythmia are disclosed in which the activity... |
| |
| Device and method for treating cardiac disorders by modulating autonomic response | 20130012938 | 20130110 |
| A method and device for modulating the autonomic nervous system adjacent a pericardial space to treat cardiac arrhythmia includes a treatment source arranged to supply a treatment medium, a catheter having an end sized for insertion into the pericardial space, a medium delivery assembly having a distal end arranged to be positioned by the catheter into the pericardium, with the distal end of the delivery assembly comprising a delivery tip arranged to extend away from the distal end of the catheter into the pericardial space. A connector operatively couples the delivery tip of the medium delivery assembly to the treatment source, and the delivery tip of the medium delivery assembly including a plurality of delivery points for delivering the treatment medium at a plurality of treatment... |
| Method for low-voltage termination of cardiac arrhythmias by effectively unpinning anatomical reentries | 20130013012 | 20130110 |
| A method for extinguishing a cardiac arrhythmia utilizes destructive interference of the passing of the reentry wave tip of an anatomical reentry through a depolarized region created by a relatively low voltage electric field in such a way as to effectively unpin the anatomical reentry. Preferably, the relatively low voltage electric field is defined by at least one unpinning shock(s) that are lower than an expected lower limit of vulnerability as established, for example, by a defibrillation threshold test. By understanding the physics of the electric field distribution between cardiac cells, the method permits the delivery of an electric field sufficient to unpin the core of the anatomical reentry, whether the precise or estimated location of the reentry is known or unknown and without the risk... |
| Methods and apparatuses for cardiac arrhythmia classification using dynamic beatdriven morphological feature extraction | 20120310102 | 20121206 |
| An implantable cardioverter/defibrillator (ICD) includes a tachyarrhythmia detection and classification system that classifies tachyarrhythmias based on a morphological analysis of arrhythmic waveforms and a template waveform. Correlation coefficients each computed between morphological features of an arrhythmic waveform and morphological features of the template waveform provide for the basis for classifying the tachyarrhythmia. In one embodiment, morphological features are collected from a sensed arrhythmic waveform, and temporally corresponding morphological features are extracted a stored template waveform.
... |
| Rap1a as a marker for cardiac arrhythmia | 20120301402 | 20121129 |
| A method for assessing if a subject has or is at risk of developing cardiac arrhythmia is described. The method includes determining the activity of Rap1A protein in a bodily sample of the subject and comparing the activity of Rap1A protein from the bodily sample of the subject to at least one Rap1A control. A decreased level of Rap1A activity in the bodily sample of the subject as compared to the at least one Rap1A control indicates that the subject is at risk of developing or has cardiac arrhythmia. Methods for evaluating the efficacy of treatment of a subject having decreased Rap1A activity with an antiarrhythmic agent are also described.
... |
| System for cardiac condition detection responsive to blood pressure analysis | 20120296225 | 20121122 |
| A system provides cardiac arrhythmia detection and performs blood pressure analysis of multiple catheter channels of blood pressure signals to characterize heart hemodynamic activity. A system for heart performance characterization and abnormality detection includes a repository, data processor and output processor. The repository of data comprises, first distribution data representing a probability distribution of a first patient parameter over a first time period and acquired on a first occasion and second distribution data representing a probability distribution of the first patient parameter over a second time period and acquired on a second occasion subsequent to the first occasion. The data processor calculates an overlap indicator indicating degree of overlap of the first distribution data and the second distribution data in a predetermined interval of the distributions.... |
| Means for the inhibition of anti-beta1-adrenergic receptor antibodies | 20120288513 | 20121115 |
| Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-β1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.
... |
| Means for the inhibition of anti-beta1-adrenergic receptor antibodies | 20120288870 | 20121115 |
| Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-β1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.
... |
| Compositions for preventing cardiac arrhythmia | 20120251507 | 20121004 |
| Disclosed herein are compositions and methods for treating or preventing a cardiac arrhythmia in a subject.
... |
| |
| Ablative treatment of the heart to improve patient outcomes following surgery | 20120232551 | 20120913 |
| Devices and methods are described for ablation of cardiac tissue for treating cardiac arrhythmias, such as atrial fibrillation. Devices may include a tissue contacting member for contacting epicardial tissue and securing the ablation device to the epicardial tissue and an ablation member for ablating the tissue. Suction apertures attach the contacting member to the epicardial surface with sufficient strength to stabilize the tissue with the device. The devices and methods can be used to ablate epicardial tissue in the vicinity of a pulmonary vein or to ablate cardiac tissues in other locations on a heart. A combined pacing and ablation probe is described for treating cardiac arrhythmia by: advancing the probe through an incision into the vicinity of the patient's heart, verifying at least one location... |
| Implanted multichamber cardiac device with selective use of reliable atrial information | 20120226179 | 20120906 |
| An implantable medical device acquires a first cardiac signal in a first heart chamber and a second cardiac signal in a second heart chamber. The device determines if the first signal is unreliable. In response to determining the first signal to be unreliable, the device switches from a first cardiac arrhythmia detection mode of operation to a second cardiac arrhythmia detection mode of operation, the first detection mode requiring the use of both the first cardiac signal and the second cardiac signal and the second detection mode requiring the use of the second cardiac signal and not requiring the use of the first cardiac signal.
... |
| Method and system for detecting cardiac arrhythmia | 20120209126 | 20120816 |
| A method of analyzing physiological data indicative of myocardial activity is disclosed. The method comprises: identifying in the data a set of N features, each corresponding to a ventricular depolarization, and calculating M time-intervals for each ventricular depolarization feature, thereby providing a vector of N*M time-intervals. The method further comprises fitting the vector to a power density function of time-intervals, and determining possible cardiac arrhythmia based on statistical parameters characterizing the function.
... |
| Implantable medical device with chemical sensor and related methods | 20120197231 | 20120802 |
| In an embodiment, the invention includes an implantable medical device with a pulse generator and a chemical sensor in communication with the pulse generator, the chemical sensor configured to detect an ion concentration in a bodily fluid. In an embodiment, the invention includes a method for providing cardiac arrhythmia therapy to a patient including sensing a physiological concentration of an analyte, communicating data regarding the physiological concentration of the analyte to an implanted pulse generator, and delivering therapy to the patient based in part on the physiological concentration of the ion. In an embodiment, the invention includes a method for monitoring diuretic therapy. In an embodiment, the invention includes a method for controlling delivery of an active agent into a human body. Other aspects and embodiments... |
| Multisite heart pacing with adjustable number of pacing sites for terminating high frequency cardiac arrhythmias | 20120197328 | 20120802 |
| High frequency cardiac arrhythmias and fibrillations are terminated by electric field pacing pulses having an order of magnitude less energy than a conventional cardioversion or defibrillation energy. The frequency and number of the pulses are selected based on a frequency analysis of a present high frequency cardiac arrhythmia or fibrillation. The energy of the pulses is selected from 1/400 to ½ of the conventional defibrillation energy, and the amplitude of the electric field pacing pulses are selected such as to activate a multitude of effective pacing sites in the heart tissue per each pacing electrode. The number and locations of the effective pacing sites in the heart tissue are regulated by the amplitude of the electric field pacing pulses, and by an orientation of the electric... |
| Synchronization of electrical stimulation therapy to treat cardiac arrhythmias | 20120172942 | 20120705 |
| Systems and methods are described for analyzing a plurality of beats after detection of a suspected cardiac arrhythmia to determine a beat discriminator, identify a beat subsequent to completion of charging of an implantable medical device by applying the beat discriminator, and synchronize delivery of a shock from the medical device to the identified beat. In some examples, identifying the beat using the beat discriminator may help to accurately synchronize the shock with a beat representative of physiological cardiac events instead of an oversensed beat, e.g., noise sensed signal that is misclassified as a cardiac beat.
... |
| Methods and compositions for correlating genetic markers with sudden cardiac death risk | 20120164640 | 20120628 |
| The present invention provides a method of identifying a subject as having an increased risk of sudden cardiac death or cardiac arrhythmia by detecting in the subject the presence of various polymorphisms associated with an increased risk of sudden cardiac death or cardiac arrhythmia.
... |
| Catheter systems for cardiac arrhythmia ablation | 20120143177 | 20120607 |
| A plurality of catheter-based ablation apparatus embodiments are provided that address several areas of atrial target tissue and which feature firm and consistent ablation element to tissue contact enabling the creation of effective continuous lesions.
... |
| Catheter systems for cardiac arrhythmia ablation | 20120143179 | 20120607 |
| A plurality of catheter-based ablation apparatus embodiments are provided that address several areas of atrial target tissue and which feature firm and consistent ablation element to tissue contact enabling the creation of effective continuous lesions.
... |
| Implantable medical device telemetry in disruptive energy field | 20120109260 | 20120503 |
| An implantable medical device may include a telemetry module, a sensing module, a therapy delivery module, and a processor. The processor may be configured to detect a patient event based on data generated by the sensing module, operate the IMD in a first mode in which the telemetry module is disabled and the therapy delivery module is at least partially disabled when the patient event is not detected, and operate the IMD in a second mode in which the telemetry module is enabled and the therapy delivery module is at least partially disabled when the patient event is detected. In some examples, the processor is configured to, in the second mode, generate a notification of the cardiac arrhythmia and transmit the notification to an external device... |
| Method and system for identifying cardiac arrhythmia driver sites | 20120089038 | 20120412 |
| A method of identifying potential driver sites for cardiac arrhythmias includes acquiring a plurality of electrograms from a plurality of locations on at least a portion of a patient's heart. Using the acquired electrograms, at least one electrical activity map is generated. Desirable electrical activity maps include complex fractionated electrogram standard deviation and mean maps, dominant frequency maps, peak-to-peak voltage maps, and activation sequence maps. Using one or more of these maps (e.g., by analyzing one or more electrogram morphological characteristics represented by these maps), at least one potential driver site can be detected.
... |
| Emergency cardiac arrhythmia identifying device and system | 20120064496 | 20120315 |
| The present invention is an emergency cardiac arrhythmia identifying device and system which can be implemented in a non-electronic visual media or in an electronic format capable of communicating ECG and EKG data observed by medical personnel over a local area network. A healthcare professional may visually identify an arrhythmia, record the occurrence of the arrhythmia in a specific patient file, communicate information to other healthcare professionals and view treatment protocols in a matter of seconds.
... |
| Treatment of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart | 20120053510 | 20120301 |
| To control cardiac arrhythmias such as atrial fibrillation post-operatively, various non-ablative agents include polymers, fibroblasts, neurotoxins, and growth factors are introduced into one or more cardiac fat pads into the atrioventricular nodal fat pad in proximity to the autonomic ganglia therein. Any desired technique may be used for introducing the agent, including injection. The sinoatrial nodal fat pad target site and the atrioventricular nodal fat pad target site are identified using a stimulator, which may have electrodes coupled thereto or which may coupled to electrodes built into a delivery system.
... |
| Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals | 20120028992 | 20120202 |
| Disclosed are pharmaceutical compositions for and methods of preventing or treating acute and/or chronic cardiac arrhythmias in a mammal, including terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm, which contain a combination of 1-[2-[(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine.
... |
| Indazolepropionic acid amide compound | 20120016117 | 20120119 |
| In formula (1), ring X represents benzene or pyridine; R1 represents an optionally substituted alkyl group; R2 represents an optionally substituted aryl group, an optionally substituted heterocyclic group, an optionally substituted arylalkyl group or an optionally substituted heterocyclic group-substituted alkyl group; R3, R4, R5, R6, R7, R8 and R9 represent each hydrogen or an alkyl group, provided that R3 and R5 may be bonded to each other to form, together with the carbon atom adjacent thereto, a cycloalkyl group; and m represents 0 or 1.
... |
| Digoxin-like fungal glycoside with cytotoxic properties: novel assay and applications | 20120003261 | 20120105 |
| The present invention provides methods of isolating cytotoxic metabolites from a fungus, and specific metabolites obtained from such methods. The present invention also provides methods of controlling fungal diseases in plants by treating the plants with cytotoxic metabolites as well as methods of treating cardiac arrhythmia in organisms in need of such treatment by administering the above-noted metabolites to such organisms.
... |
| Control of cardiac arrhythmia by vagal stimulation at the atrioventricular and sinoatrial nodal fat pads of the heart | 20100312299 | 20101209 |
| Vagal stimulation applied to the atrioventricular nodal (“AVN”) fat pad and the sinoatrial nodal (“SAN”) fat pad via epicardial leads is useful for controlling cardiac arrhythmia, including atrial fibrillation (‘AF”). In the case of AF, for example, vagal stimulation may be applied initially to the AVN fat pad to reduce ventricular rate, and vagal stimulation may be applied to the SAN fat pad after restoration of sinus rhythm to control atrial rate. The technique is applicable to control acute AF and chronic AF. The vagal stimulation may be optimized for exciting ganglia in the fat pads to produce dromotropic and chronotropic effects in the atrioventricular node and the sinoatrial node, respectively. In addition, the SAN fat lead can also be used to pace the atrium in... |
| Intrapericardial antiarrhythmic delivery | 20100310629 | 20101209 |
| Certain embodiments provide a method, of treating or reducing a risk of postoperative cardiac arrhythmia, including: creating an opening in a mammal's body; advancing a releasing member from outside the body, through the opening, and toward the mammal's heart; positioning the releasing member between a visceral layer and a parietal layer of pericardium of the mammal's heart; and at least partially closing the opening in the body, leaving the releasing member in the pericardial space. In certain embodiments, the releasing member releases an antiarrhythmic drug into the mammal's pericardial space and is configured not to impede significantly a systolic or a diastolic function of the heart while the releasing member resides in the pericardial space.
... |
| Use of hdac inhibitors for treatment of cardiac rhythm disorders | 20100298237 | 20101125 |
| The present invention provides methods of ameliorating or reducing the extent of cardiac arrhythmia disorders, by administering an inhibitor of histone deacetylase enzyme (HDAC).
... |
| Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges | 20100268289 | 20101021 |
| Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which... |
| Cardiac arrhythmia report | 20100268103 | 20101021 |
| Systems, devices, methods, and techniques relating to generating and presenting information related to heart rate data. In one aspect, a system includes a monitoring device configured to obtain physiological data for a living being and to generate annotation data based on the physiological data for a total time period, a processing system configured to obtain the annotation data via a communication channel from the monitoring device and to generate for display based on the annotation data a daily patient report that includes, a chart showing summary statistical data for a proportion of a total monitored time period spent in cardiac arrhythmia for each of a plurality of days and summary statistical data for a proportion of the total monitored time period not spent in cardiac arrhythmia... |
| Tricyclic guanidine derivatives as sodium-proton exchange inhibitors | 20100267690 | 20101021 |
| are disclosed, wherein U is C(O), CRaRb, O, NRa or S(O)m; V is CRaRb or NRa; W is S(O)m; wherein Ra is H, alkyl, cycloalkyl, alkenyl or aralkyl; Rb is H, alkyl, OH, ORa or OCORa, and m is the integer 0, 1 or 2; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein with the proviso that at least one of R1, R2, R3, R4, R5, R6, R7 or R8 is guanidino or guanidino carbonyl. These derivatives are sodium-proton exchange inhibitors and are useful as medicaments for the treatment of, for example, organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy, hypertension, cell proliferative disorders and diabetes.
... |
| Isoquinolinone potassium channel inhibitors | 20100256698 | 20101007 |
| useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
... |
| Non-invasive measurement of suprasystolic signals | 20100256507 | 20101007 |
| An apparatus for assessing cardiovascular status of a mammal comprises a system for locally applying a pressure to an artery capable of restricting blood flow through said artery, a wideband external pulse transducer having an output and situated to measure suprasystolic signals proximate to said artery, and a computing device receiving said output for calculating vascular compliance values. The method described is particularly useful for determining cardiac output, assessing whether a pregnant female has preeclampsia or a patient has cardiac insufficiency, or assessing cardiac arrhythmias.
... |
| Indazole acrylic acid amide compound | 20100256108 | 20101007 |
| wherein ring X is benzene or pyridine; R1 is substituted alkyl; R2 is optionally substituted aryl or optionally substituted heterocyclic group; R3 is hydrogen or alkyl; R4 is hydrogen, halogen or alkyl; R5 is hydrogen or alkyl; R6 and R7 are the same or different and each hydrogen or halogen, or a pharmaceutically acceptable salt thereof, which is useful as IKur blocker effective for preventing or treating cardiac arrhythmia such as atrial fibrillation.
... |
| External defibrillator | 20100241181 | 20100923 |
| A variety of arrangements and methods relating to a defibrillator are described. In one aspect of the invention, a defibrillator includes two paddles that each include a defibrillator electrode covered in a protective housing. The two paddles are sealed together using a releasable seal to form a paddle module such that the housings of the paddles form the exterior of the paddle module. An electrical system including at least a battery and a capacitor is electrically coupled with the paddles. The battery is arranged to charge the capacitor. The capacitor is arranged to apply a voltage at the defibrillator electrodes, which generates an electrical shock for arresting a cardiac arrhythmia.
... |
| Combined hemodynamic and egm-based arrhythmia detection | 20100241180 | 20100923 |
| A medical device and associated method for detecting arrhythmias that includes electrodes for sensing cardiac electrical signals and a hemodynamic sensor for sensing a hemodynamic signal. An episode of cardiac electrical event intervals meeting cardiac arrhythmia detection criteria is detected from the sensed electrical signals. Cardiac mechanical events and/or cardiac mechanical event intervals are measured from the hemodynamic signal and used to withhold or confirm a cardiac arrhythmia detection of the episode.
... |
| Compositions and methods for preventing cardiac arrhythmia | 20100233235 | 20100916 |
| Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject.
... |
| Uses of pegylated albumin | 20100222260 | 20100902 |
| The present invention is directed to uses of PEGylated albumins which include methods of treating reduced functional capillary density, reduced blood volume, septic shock and cardiac arrhythmia in a subject, which comprise administering to the subject a therapeutically effective amount of a PEGylated albumin.
... |
| Methods and systems for treating cardiac arrhythmias | 20100217342 | 20100826 |
| The disclosure includes methods and systems for treating cardiac arrhythmias. Some methods for treating an abnormal heart rhythm include determining a change in a sinus node cycle length of a heart of a patient between a time prior to the abnormal heart rhythm and a time during the abnormal heart rhythm; when the change is within a first range, delivering a first therapy to the patient for treating the abnormal heart rhythm; and when the change is within a second range, delivering a second therapy to the patient for treating the abnormal heart rhythm, wherein the first therapy is different from the second therapy. In some embodiments, the first therapy may include shock therapy and the second therapy may include anti-tachycardia pacing.
... |
| Method and apparatus for identifying potentially misclassified arrhythmic episodes | 20100211125 | 20100819 |
| An implantable cardiac device is configured to classify cardiac arrhythmias using a plurality of arrhythmia discrimination algorithms. Data is provided that is associated with a plurality of cardiac arrhythmic episodes for which a cardiac electrical therapy was delivered or withheld by the implantable medical device based on the plurality of arrhythmia discrimination algorithms. A metric for each of the arrhythmic episodes is computed. The metric defines a measure by which the implantable cardiac device properly classified the arrhythmia. Potentially misclassified arrhythmic episodes of the plurality of cardiac arrhythmic episodes for which cardiac electrical therapy was inappropriately delivered or withheld are algorithmically identified using the metric.
... |
| Pacing management during cardiopulmonary resuscitation | 20100211124 | 20100819 |
| Systems and methods provide for coordinated cardiac pacing with delivery of cardiopulmonary resuscitation (CPR) to a patient. Managing cardiac pacing in a patient during a cardiac arrhythmia involves detecting a cardiac arrhythmia using a patient implantable medical device, prompting a cardiopulmonary resuscitation compression, and delivering, using the patient implantable medical device, a pacing pulse to a heart chamber in coordination with the compression prompt.
... |
| Ablation catheter assembly with radially decreasing helix and method of use | 20100204692 | 20100812 |
| A catheter assembly for treatment of cardiac arrhythmia. The catheter assembly includes a catheter body and an ablative energy source. The catheter body includes a proximal portion, an intermediate portion, and a distal portion. The intermediate portion extends from the proximal portion and defines a longitudinal axis. The distal portion extends from the intermediate portion and includes an ablation section and a tip. The ablation section forms a loop defining a diameter greater than an outer dimension of a pulmonary vein ostium. The tip extends distally from the ablation section and is configured to locate a pulmonary vein. Finally, the ablative energy source is associated with the ablation section. With this configuration, upon activation of the energy source, the ablation section ablates a desired lesion pattern.... |
| Short acting phenylalkylamine calcium channel blockers and uses thereof | 20100190852 | 20100729 |
| The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
... |
| Methods of treating a cardiac arrhythmia by thoracoscopic production of a cox maze iii lesion set | 20100185186 | 20100722 |
| Methods of treating a subject for a cardiac arrhythmia are provided. Aspects of the methods include thoracoscopically producing a cardiac Cox maze III set of lesions in cardiac tissue of the subject in a manner sufficient to treat the subject for the cardiac arrhythmia.
... |
| Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling | 20100183565 | 20100722 |
| The present invention is directed to methods of producing cardiomyocytes having a nodal/pacemaker phenotype and cardiomyocytes having an atrial/ventricular phenotype. Isolated populations of nodal/pacemaker and atrial/ventricular cardiomyocytes are also disclosed. Methods of treating a subject having cardiac arrhythmia and a subject in need of cardiac tissue repair using the isolated populations of nodal/pacemaker cardiomyocytes and atrial/ventricular cardiomyocytes, respectively, are also disclosed.
... |
| Method and system for detecting and treating junctional rhythms | 20100179607 | 20100715 |
| A method and an apparatus for treating cardiac arrhythmias are provided. An interval between first and second consecutive beats of a heart, having first and second chamber types, is determined. The heart is paced at a first rate if the first beat is from the first chamber type and the second beat is from the second chamber type and the interval is less than a predetermined amount of time or if the first and second beats are both from the second chamber type. The heart is paced at a second rate if the first beat is from the first chamber type and the second beat is from the second chamber type and the interval is more than the predetermined amount of time.
... |
| Methods of measurement of drug induced changes in cardiac ion channel function and associated apparatus | 20100179447 | 20100715 |
| This invention relates to the healthcare industry and to a novel non-invasive body surface bipolar ECG to monitor the action potential (AP) of the myocardium muscle. The invention uses surface ECG signals to deduce information on the cardiac ion channels, founded on the reconstruction of the epicardial ECG T-wave using a single transfer filter function of the frequency domain. Ion channels conductances obtained are then used to calculate action potential EndAP, EpiAP and MAP of the myocardium. These APs values can in turn be used to calculate post drug transmural dispersion of repolarisation values to giving an indication of possible cardiac arrhythmias. The invention further relates to various apparatus for carrying out the invention, including an array of bipolar electrodes which in use is arranged on... |
| Catheter for percutaneous transcatheter ablation of cardiac arrhythmias using bipolar radiofrequency | 20100174280 | 20100708 |
| A catheter that distributes bipolar radiofrequency for use during the percutaneous ablation of cardiac arrhythmias. The catheter comprising a flexible sheath, a handle, a pull-wire, holes for irrigation in its distal tip, sensing means and electrodes.
... |
| Method and system for detecting cardiac arrhythmias during overdrive pacing | 20100168810 | 20100701 |
| A method and apparatus are provided for detecting cardiac arrhythmias during overdrive pacing. A maximum paced rate and a reduced paced rate for a heart are determined, the maximum paced rate being higher than the reduced paced rate. The heart is paced at the maximum paced rate. After the heart is paced at the maximum paced rate for a predetermined amount of time, the heart is paced at the reduced paced rate.
... |
| Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (ryr2) | 20100152440 | 20100617 |
| The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents... |
| Arrhythmia classification and therapy selection | 20100145400 | 20100610 |
| Different types of cardiac arrhythmia are classified based on the morphology of the arrhythmic beats. Cardiac beats associated with an arrhythmic episode are compared to a plurality of representative beat morphologies, each representative beat morphology characterizing a type of arrhythmia of the heart. An arrhythmic episode may be classified as a particular type of arrhythmia if the morphology of the arrhythmic cardiac beats matches a representative beat morphology characterizing the particular type of arrhythmia. An appropriate therapy for the particular type of arrhythmia may be selected based on the arrhythmia classification. A particular type of arrhythmia may be associated with one or more therapies used to treat the arrhythmia. The therapy used to treat the arrhythmia may comprise a therapy identified as a previously successful therapy.
... |
| Interferential cardiac preconditioning and depolarization | 20100114207 | 20100506 |
| Exemplary systems, devices, and methods pertaining to cardiac related therapy and particularly to interferential cardiac preconditioning and depolarization are described. A cardiac arrhythmia is detected from electrogram data sensed from a patient's heart and a region of the heart affected by the cardiac arrhythmia is determined. The affected region is the interferentially energized by multiple cycles of two concurrently delivered alternating currents which are offset in frequency.
... |
| Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities | 20100112081 | 20100506 |
| Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically. In some embodiments, the PRP composition may be coated on one or more medical devices. The PRP composition may be delivered to an identified portion of the electrical conduction system of the heart affected and/or causing the arrhythmia to occur.
... |
| Methods for preventing or treating cardiac arrhythmia | 20100069403 | 20100318 |
| Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof.
... |
| Extravascular arrhythmia induction | 20100030290 | 20100204 |
| A cardiac arrhythmia may be induced by delivering a sequence of pulses to a patient via one or more extravascular electrodes. In one example, one or more pacing pulses may be delivered to a patient via an extravascular electrode and a shock pulse may be delivered to the patient the extravascular electrode. In some examples, the pacing pulses and the shock pulse may be generated with energy from a common energy storage module and without interim charging of the module. For example, the pacing and shock pulses may be generated as the energy storage module dissipates. In another example, a cardiac arrhythmia may be induced in a patient by delivering a burst of pulses to a patient via an extravascular electrode. In some cases, the burst... |
| Tissue perfusion sensor control | 20090326350 | 20091231 |
| An optical perfusion sensor may monitor blood oxygen saturation of blood-perfused tissue, which may be referred to as tissue perfusion, until a tissue perfusion value is within a threshold range of a reference value, and, in some examples, for at least a minimum period of time. The tissue perfusion value may indicate an absolute blood oxygen saturation level or a relative change in blood oxygen saturation level. The reference value may be, for example, determined by an oxygen (O2) variation index that indicates a change in blood oxygen saturation of tissue. In some examples, the optical perfusion sensor may be activated upon detecting a cardiac event, such as a cardiac arrhythmia. In addition, in some examples, cardiac signal monitoring may be activated upon detecting a threshold... |
| New oxabispidine compunds useful in the treatment of cardiac arrhythmias | 20090326221 | 20091231 |
| wherein R1, R2, R3, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
... |
| Genetic markers for risk management of cardiac arrhythmia | 20090325163 | 20091231 |
| The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.
... |
| Cardiac stimulator for treatment of tachycardiac arrhythmias of the heart | 20090312812 | 20091217 |
| An implantable antitachycardiac cardiac stimulator has at least one right-ventricular sensing unit, a defibrillation shock generator and a control unit, as well as an additional detection unit for detecting ventricular events which operates independently of the right-ventricular detection electrode, and an evaluation unit (e.g., as an additional component of the control unit) which suppresses the delivery of a defibrillation shock on reliable detection of the normal rhythm via the additional detection unit.
... |
| Electrotherapy device for treating tachycardiac arrhythmias of a heart | 20090306729 | 20091210 |
| An electrotherapy system, particularly an implantable heart stimulator, is configured as an electronic implant for electrical anti-tachycardia therapy of the heart, and includes at least one programmable therapy sequence (i.e. a sequence of several therapies that are delivered, one after the other, to treat a VT/VF episode). The implant has a therapy success memory for storing therapy success statistics for each therapy, as well as a therapy control unit that is configured to automatically undertake adaptation of the order of the therapies within a therapy sequence as a function of currently stored therapy success statistics.
... |
| Methods for detection of cardiac arrhythmias | 20090275849 | 20091105 |
| A method for calculating a variability value that is indicative of AF by obtaining a signal sequence of a plurality of RR intervals by monitoring electrical activity of a patient's heart. Each RR interval is converted into an instantaneous heart rate value and sorted into ascending order. The difference between each successive heart rate is calculated, discarding the two largest differences. The variability value is calculated by adding the retained differences.
... |
| Methods for detection of cardiac arrhythmias | 20090275849 | 20091105 |
| A method for calculating a variability value that is indicative of AF by obtaining a signal sequence of a plurality of RR intervals by monitoring electrical activity of a patient's heart. Each RR interval is converted into an instantaneous heart rate value and sorted into ascending order. The difference between each successive heart rate is calculated, discarding the two largest differences. The variability value is calculated by adding the retained differences.
... |
| Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | 20090270383 | 20091029 |
| There is provided compounds of formula (I), wherein R1, R2, R3, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
... |
| Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | 20090270383 | 20091029 |
| There is provided compounds of formula (I), wherein R1, R2, R3, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
... |
| System for heart monitoring, characterization and abnormality detection | 20090259266 | 20091015 |
| A system analyzes and characterizes cardiac electrophysiological signals by determining instantaneous signal entropy for identifying and characterizing cardiac disorders, differentiating cardiac arrhythmias, determining pathological severity and predicting life-threatening events. A system for heart monitoring, characterization and abnormality detection, includes an acquisition device for acquiring an electrophysiological signal representing a heart beat cycle of a patient heart. A signal processor derives an entropy representative value of the acquired electrophysiological signal within a time period comprising at least a portion of a heart beat cycle of the acquired electrophysiological signal and provides an entropy value as a function of the entropy representative value and the time period. A comparator generates data representing a message for communication to a destination device in response to the entropy value exceeding a... |
| Use of tools, mapping systems, catheters, electrodes or any devices targeting any autonomic nerve(s) structure(s) in the human heart for the diagnostic, treatment and/or prevention of the recurrence of cardiac arrhythmias. | 20090253974 | 20091008 |
| Treatment of atrial fibrillation, targeting the triggering autonomic nerve structures have been shown high efficacy for converting to a sinus rhythm state. However, the efficacy is limited to a short time (<3 months) with a high degree of recurrence of atrial arrhythmias. The recurrence rate was directly correlated to the time of follow-up which would support the role of the autonomic nerve regenerative (or re-establishment) activities for the incidence of the recurrence of atrial arrhythmias (ex. persistent atrial fibrillation). Furthermore, the recurrence degree of atrial fibrillation has not been shown any statistically significant difference between any of the currently used methods within any targeted area. Therefore, the long term inefficacy matter could be related either to the existing technologies or to their uses. The autonomic nerve’... |
| Use of tools, mapping systems, catheters, electrodes or any devices targeting any autonomic nerve(s) structure(s) in the human heart for the diagnostic, treatment and/or prevention of the recurrence of cardiac arrhythmias. | 20090253974 | 20091008 |
| Treatment of atrial fibrillation, targeting the triggering autonomic nerve structures have been shown high efficacy for converting to a sinus rhythm state. However, the efficacy is limited to a short time (<3 months) with a high degree of recurrence of atrial arrhythmias. The recurrence rate was directly correlated to the time of follow-up which would support the role of the autonomic nerve regenerative (or re-establishment) activities for the incidence of the recurrence of atrial arrhythmias (ex. persistent atrial fibrillation). Furthermore, the recurrence degree of atrial fibrillation has not been shown any statistically significant difference between any of the currently used methods within any targeted area. Therefore, the long term inefficacy matter could be related either to the existing technologies or to their uses. The autonomic nerve’... |
| Epicardial ablation using focused ultrasound | 20090247912 | 20091001 |
| Apparatus for treating cardiac arrhythmias includes an ultrasonic ablation device incorporating an ultrasonic emitter (22, 400), means (10, 14, 402, 404) for positioning the ablation device outside of the heart but adjacent the epicardial surface of the heart, and means (26, 28, 30) for focusing the ultrasonic energy emitted by the emitter into an ablation region, so that the ablation region is disposed within the wall of the heart.
... |
| Methods and apparatus for ablation of cardiac tissue | 20090240248 | 20090924 |
| Embodiments of the invention relate to electrophysiology catheters and methods of using the same. According to one embodiment, a method of treating a cardiac arrhythmia comprises forming a first lesion about a source of an electrical signal in the heart, the first lesion having an open first perimeter, and forming a second lesion about the source of the electrical signal in the heart. The second lesion has an open second perimeter and is located closer to the source of the electrical signal than the first lesion. The first lesion is discontinuous from the second lesion, and at least the first and second lesions together form a closed, at least substantially complete conduction block. According to other embodiments, catheters are provided for performing this and other methods.
... |
| Potassium channel inhibitors | 20090233897 | 20090917 |
| The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
... |
| Heart failure decompensation prediction based on cardiac rhythm | 20090234410 | 20090917 |
| Systems and methods of detecting an impending cardiac decompensation of a patient measure an electrocardiogram signal of the patient. An incidence of cardiac arrhythmias is determined from the electrocardiogram signal. A risk of impending decompensation is determined in response to the incidence of cardiac arrhythmias. In many embodiments, the impending decompensation can be detected early enough to avoid, or at least delay, the impending decompensation, such that patient trauma and/or expensive ICU care can be avoided. Although embodiments make specific reference to monitoring electrocardiogram and other physiological signals with an adherent patch, the system methods and devices are applicable to many applications in which physiological monitoring is used, for example wireless physiological monitoring with implanted sensors for extended periods.
... |
| Potassium channel inhibitors | 20090233897 | 20090917 |
| The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
... |
| Heart failure decompensation prediction based on cardiac rhythm | 20090234410 | 20090917 |
| Systems and methods of detecting an impending cardiac decompensation of a patient measure an electrocardiogram signal of the patient. An incidence of cardiac arrhythmias is determined from the electrocardiogram signal. A risk of impending decompensation is determined in response to the incidence of cardiac arrhythmias. In many embodiments, the impending decompensation can be detected early enough to avoid, or at least delay, the impending decompensation, such that patient trauma and/or expensive ICU care can be avoided. Although embodiments make specific reference to monitoring electrocardiogram and other physiological signals with an adherent patch, the system methods and devices are applicable to many applications in which physiological monitoring is used, for example wireless physiological monitoring with implanted sensors for extended periods.
... |
| Polymorphisms and haplotypes of the alpha 2c adrenergic receptor gene | 20090228995 | 20090910 |
| Methods and compositions for diagnosing and treating diseases are provided. The methods involve the discovery of a correlation between an α2C-adrenergic receptor gene polymorphism, a combination of polymorphisms or a haplotype and the occurrence of diseases such as heart failure, cardiac arrhythmias, hypertension, behavioral and learning disorders, psychiatric diseases such as depression, obesity, and diabetes mellitus. The invention further pertains to the use of such molecules and methods in the diagnosis, prognosis, and treatment selection for diseases such as heart failure, cardiac arrhythmias, hypertension, behavioral and learning disorders, psychiatric diseases such as depression, obesity, and diabetes mellitus. The invention also pertains to a composition of matter comprising polymorphisms and haplotypes of the α2C-adrenergic receptor.
... |
| Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy | 20090216318 | 20090827 |
| The invention provides methods for inhibiting cardiomyopathy and for inhibiting cardiac arrhythmia, by administering to an individual in need thereof a cis-epoxyeicosantrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. In some embodiments, the method comprises administering to the individual a nucleic acid encoding an inhibitor of sEH. Cardiomyopathies treatable by the methods of the invention include cardiac hypertrophy and dilated cardiomyopathy.
... |
| Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy | 20090216318 | 20090827 |
| The invention provides methods for inhibiting cardiomyopathy and for inhibiting cardiac arrhythmia, by administering to an individual in need thereof a cis-epoxyeicosantrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. In some embodiments, the method comprises administering to the individual a nucleic acid encoding an inhibitor of sEH. Cardiomyopathies treatable by the methods of the invention include cardiac hypertrophy and dilated cardiomyopathy.
... |
| Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy | 20090216318 | 20090827 |
| The invention provides methods for inhibiting cardiomyopathy and for inhibiting cardiac arrhythmia, by administering to an individual in need thereof a cis-epoxyeicosantrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. In some embodiments, the method comprises administering to the individual a nucleic acid encoding an inhibitor of sEH. Cardiomyopathies treatable by the methods of the invention include cardiac hypertrophy and dilated cardiomyopathy.
... |
| Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy | 20090216318 | 20090827 |
| The invention provides methods for inhibiting cardiomyopathy and for inhibiting cardiac arrhythmia, by administering to an individual in need thereof a cis-epoxyeicosantrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. In some embodiments, the method comprises administering to the individual a nucleic acid encoding an inhibitor of sEH. Cardiomyopathies treatable by the methods of the invention include cardiac hypertrophy and dilated cardiomyopathy.
... |
| Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy | 20090216318 | 20090827 |
| The invention provides methods for inhibiting cardiomyopathy and for inhibiting cardiac arrhythmia, by administering to an individual in need thereof a cis-epoxyeicosantrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. In some embodiments, the method comprises administering to the individual a nucleic acid encoding an inhibitor of sEH. Cardiomyopathies treatable by the methods of the invention include cardiac hypertrophy and dilated cardiomyopathy.
... |
| Ablative ultrasonic-cryogenic apparatus | 20090209885 | 20090820 |
| An ablative apparatus that can be used to treat atrial fibrillation and other cardiac arrhythmias by ablating cardiac tissue is disclosed. When the distal end of the apparatus reaches the tissue to be ablated, an ablation probe driven by a transducer is vibrated. Scratching the tissue with abrasive members, the vibrating ablation probe is capable of mechanically ablating tissues. This mechanical ablation may be utilized to penetrate epicardial fat, thereby exposing the underlying myocardium. The ablative apparatus may then be used subject the exposed myocardium to mechanical ablation, cryoablation, ultrasonic ablation, and/or any combination thereof.
... |
| Ablative ultrasonic-cryogenic apparatus | 20090209885 | 20090820 |
| An ablative apparatus that can be used to treat atrial fibrillation and other cardiac arrhythmias by ablating cardiac tissue is disclosed. When the distal end of the apparatus reaches the tissue to be ablated, an ablation probe driven by a transducer is vibrated. Scratching the tissue with abrasive members, the vibrating ablation probe is capable of mechanically ablating tissues. This mechanical ablation may be utilized to penetrate epicardial fat, thereby exposing the underlying myocardium. The ablative apparatus may then be used subject the exposed myocardium to mechanical ablation, cryoablation, ultrasonic ablation, and/or any combination thereof.
... |
| Apparatus, system, and method for monitoring physiological signs | 20090203972 | 20090813 |
| An apparatus, system, and method monitors the motion, breathing, heart rate and sleep state of subjects, e.g., humans, in a convenient, non-invasive/non-contact, and low-cost fashion. More particularly, the motion, breathing, and heart rate signals are obtained through processing applied to a raw signal obtained in a non-contact fashion, typically using a radio-frequency sensor. Periods of sleep disturbed respiration, or central apnea can be detected through analysis of the respiratory signal. The mean heart rate, and derived information, such as the presence of cardiac arrhythmias can be determined from the cardiac signal. Motion estimates can be used to recognize disturbed sleep and periodic limb movements. The sleep state may be determined by applying a classifier model to the resulting streams of respiratory, cardiac and motion data. A... |
| Implantable cardiac stimulation device with respiratory modulated therapy delivery | 20090204166 | 20090813 |
| A method of providing cardiac stimulation therapy and a device for providing the therapy. A patient's cardiac activity as well as cyclical respiration is monitored. Cardiac stimulation is provided as indicated as therapeutic intervention for a variety of cardiac arrhythmias according to variable timing parameters. One or more of the timing parameters under which cardiac pacing stimulations are provided is varied or modulated with the cyclical variations in respiration. The one or more timing parameters are generally shortened or elongated in concert with the alternating inspiration/exhalation phases of respiration. In certain implementations, the patient's respiration is inferred from cardiac based physiologic signals. The methods and devices for providing cardiac stimulation therapy more accurately emulate natural healthy physiologic activity.
... |
| Baroreflex activation for arrhythmia treatment | 20090198294 | 20090806 |
| Devices, systems and methods provide baroreflex activation to prevent, or at least reduce the likelihood of occurrence of, cardiac arrhythmias. Various embodiments may additionally or alternatively promote recovery from arrhythmias. In one embodiment, a device for preventing or reducing the likelihood of occurrence of arrhythmias includes one or more baroreflex activation devices, one or more sensors coupled to the baroreflex activation device(s), and a processor for processing information from the sensor and activating and/or modulation the baroreflex activation device. Sensors, such as electrocardiogram devices, generally sense factors indicative of a potential, ensuing arrhythmia.
... |
| Cardiac arrhythmia treatment methods and biological pacemaker | 20090175790 | 20090709 |
| Disclosed are methods of preventing or treating cardiac arrhythmia. In one embodiment, the methods include administering to an amount of at least one polynucleotide that modulates an electrical property of the heart. The methods have a wide variety of important uses including treating cardiac arrhythmia. Also disclosed are methods and systems for modulating electrical behavior of cardiac cells. Preferred methods include administering a polynucleotide or cell-based composition that can modulate cardiac contraction to desired levels, e.g., the administered composition functions as a biological pacemaker.
... |
| Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | 20080319198 | 20081225 |
| wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
... |
| Use of aza-phenylalanine compounds for treating cardiac arrhythmia | 20080306047 | 20081211 |
| The present invention relates to the use of certain aza-phenylalanine compounds of formula (I) wherein R1 denotes amino, alkylamino, dialkylamino, amidino, alkylamidino, N-hydroxyamidino, or N-alkoxyamidino, Y denotes sulfonyl or carbonyl and R2 and R4 independently represent various organic residues, in the treatment or prevention of cardiac arrhythmia and/or in treatment or prevention of diseases in association with ischemic heart conditions.
... |
| Rf ablation catheter with side-eye infrared imager | 20080287942 | 20081120 |
| An ablation catheter has an imager useful in connection with an ablation operation such as used in the treatment of a cardiac arrhythmia. The catheter has an ablation electrode positioned on a catheter tip, and the imager is located on a side of the catheter. Because the catheter tip is generally articulated when the lesion is formed, this position of the imager provides an image that corresponds with the position of the catheter when it is used to form a lesion. Rings for recording tissue electrograms are also positioned on the catheter tip. This arrangement allows the user to accurately place and contact the electrode and to monitor the ablation process such as by viewing bubbles and thrombi that may undesirably be formed.
... |
| Cardiac arrhythmias analysis of electrophysiological signals based on symbolic dynamics | 20080281216 | 20081113 |
| The disclosed method analyzes cardiac electrophysiological signals, including ECG and internal cardiac electrograms, based on multi-level symbolic complexity calculation and multi-dimensional mapping. The results may be used to objectively identify cardiac disorders, differentiate cardiac arrhythmias, characterize pathological severities, and predict life-threatening events. Multi-level symbolization and calculation of the electrophysiological signal is used provide better reliability and analysis resolution for identifying and characterizing cardiac disorders. Adaptive analysis of the cardiac signal complexity enables calculation efficiency and reliability with high SNR, and with low calculation volume and power consumption. One dimension (time or frequency domain) and multi-dimension symbolic analysis is used to provide more information of cardiac pathology and high risk rhythm transition to doctors.
... |
| Parenteral solution containing amiodarone in nndma (n,n,-dimethylacetamide) | 20080255229 | 20081016 |
| Disclosed herein are parenteral solutions containing 3-diethylaminoethoxy benzoyl-benzofurans, such as amiodarone, in a diluent NNDMA (N,N-Dimethylacetamide) useful in the treatment of cardiac arrhythmias both supraventricular, ventricular as well as, the condition of cardiac arrest.
... |
| Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | 20080249086 | 20081009 |
| There is provided compounds of formula I, wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
... |
| Isoquinolinone potassium channel inhibitors | 20080227778 | 20080918 |
| The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
... |
| Controlled release nisoldipine compositions | 20080221174 | 20080911 |
| Controlled release oral dosage formulations containing calcium channel blockers, and methods of use thereof, are provided for the once-a-day treatment of cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmia. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. The formulation provides an increase in the bioavailability of the calcium channel blocker as compared to the bioavailability of the calcium channel blocker in other drug delivery formulations known in the art. In one embodiment, the formulation provides an increase in the bioavailability of the calcium channel blocker, nisoldipine, as compared to the same dose of nisoldipine in the coat-core version of the drug (SULAR®). The formulation can be in the form of a trilayer tablet containing a core or central layer and... |
| Apparatus and method of arrhythmia detection in a subcutaneous implantable cardioverter/defibrillator | 20080221632 | 20080911 |
| In a subcutaneous implantable cardioverter/defibrillator, cardiac arrhythmias are detected to determine necessary therapeutic action. Cardiac signal information is sensed from far field electrodes implanted in a patient. The sensed cardiac signal information is then amplified and filtered. Parameters such as rate, QRS pulse width, cardiac QRS slew rate, amplitude and stability measures of these parameters from the filtered cardiac signal information are measured, processed and integrated to determine if the cardioverter/defibrillator needs to initiate therapeutic action.
... |
| Methods for preventing or treating cardiac arrhythmia | 20080214554 | 20080904 |
| Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof.
... |
| Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | 20080207899 | 20080828 |
| There is provided compounds of formula I, wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
... |
| Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | 20080200553 | 20080821 |
| in which R1 to R4 have the meanings stated in the claims, are suitable as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.
... |
| Delivery system for delivering a medical device to a location within a patient's body | 20080188850 | 20080807 |
| Devices, systems and methods are provided for deployment of one or more functional devices, such as therapeutic or diagnostic medical devices, or positioning devices, at various locations relative to a defined operative path. The devices, systems, and methods can include a guide system and a positioning element. The guide system defines the operative path when deployed within a patient's body. The positioning element cooperates with the guide system to define one or more positions relative the defined operative path from which the one or more functional devices are deployed. The present inventions allow for the accurate and reliable placement of the one or more functional devices at the one or more positions relative the operative path. In one embodiment, the functional device is an ablation device... |
| Sensing vector selection in a cardiac stimulus device with postural assessment | 20080188901 | 20080807 |
| Methods, implantable medical devices and systems configured to perform analysis of captured signals from implanted electrodes to identify cardiac arrhythmias. In an illustrative embodiment, signals captured from two or more sensing vectors are analyzed, where the signals are captured with a patient in at least first and second body positions. Analysis is performed to identify primary or default sensing vectors and/or templates for event detection.
... |
| Use of d-ribose to treat cardiac arrhythmias | 20080176809 | 20080724 |
| D-ribose, given in doses of five to 15 grams daily, reduces or prevents the occurrence of atrial fibrillation in persons experiencing atrial fibrillation.
... |
| Pentafluorosulfanylbenzoylguanidines, process for their preparation, use as a medicament or diagnostic aid, and medicament comprising same | 20080146673 | 20080619 |
| wherein R1 to R4 have the meanings stated in the claims, are suitable, for example, as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.
... |
| Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | 20080146812 | 20080619 |
| There is provided compounds of formula I, wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
... |
| Energy delivery systems and uses thereof | 20080147056 | 20080619 |
| The present invention relates to comprehensive systems, devices and methods for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In certain embodiments, systems, devices, and methods are provided for treating a tissue region (e.g., a tumor) through application of energy.
... |
| Use of amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2h-chromen-6-yl-compounds in the treatment of cardiac arrhythmia and other disease states | 20080113999 | 20080515 |
| in which R1, R2, R3, R4, R5 and R6 have the meanings given in the description for treating cardiac arrhythmias and other disease states.
... |
| Novel compounds for treatment of cardiac arrhythmia and methods of use | 20080114059 | 20080515 |
| The subject invention provides novel compounds for treatment of cardiac arrhythmia and methods of use.
... |
| Specific binding members for ngf | 20080107658 | 20080508 |
| Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralise NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.
... |
| Potassium channel inhibitors | 20080090794 | 20080417 |
| useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
... |
| Controlled release nisoldipine compositions | 20080063711 | 20080313 |
| Controlled release oral dosage formulations containing calcium channel blockers, and methods of use thereof, are provided for the once-a-day treatment of cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmia. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. The formulation provides an increase in the bioavailability of the calcium channel blocker as compared to the bioavailability of the calcium channel blocker in other drug delivery formulations known in the art. In one embodiment, the formulation provides an increase in the bioavailability of the calcium channel blocker, nisoldipine, as compared to the same dose of nisoldipine in the coat-core version of the drug (SULAR®). The formulation can be in the form of a trilayer tablet containing a core or central layer and... |
| Impedance-based cardiac therapy planning method with a remote surgical navigation system | 20080065061 | 20080313 |
| A method is disclosed for planning the treatment of cardiac arrhythmias by RF ablation with a remote navigation system, including the identification of ablation lines around the pulmonary veins ostia—atrial junctions based on impedance measurements. When used by itself or in conjunction with electro-anatomical approaches, the impedance method therein disclosed enables safe and effective arrhythmia treatment.
... |
| Method and apparatus for identifying potentially misclassified arrhythmic episodes | 20080065165 | 20080313 |
| An implantable cardiac device is configured to classify cardiac arrhythmias using a plurality of arrhythmia discrimination algorithms. Data is provided that is associated with a plurality of cardiac arrhythmic episodes for which a cardiac electrical therapy was delivered or withheld by the implantable medical device based on the plurality of arrhythmia discrimination algorithms. A metric for each of the arrhythmic episodes is computed. The metric defines a measure by which the implantable cardiac device properly classified the arrhythmia. Potentially misclassified arrhythmic episodes of the plurality of cardiac arrhythmic episodes for which cardiac electrical therapy was inappropriately delivered or withheld are algorithmically identified using the metric.
... |
| Energy delivery systems and uses thereof | 20080045938 | 20080221 |
| The present invention relates to systems and devices for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In particular, the present invention relates to systems and devices for the delivery of energy with a linear array of antenna components having optimized energy delivery characteristics. In certain embodiments, methods are provided for treating a tissue region (e.g., a tumor) through application of energy with the systems and devices of the present invention.
... |
| Ablative cardiac catheter system | 20080039727 | 20080214 |
| The present invention relates to a catheter system that can be used to treat atrial fibrillation and other cardiac arrhythmias by ablating cardiac tissue comprising a catheter, a guide wire, and an ultrasonically driven mechanical ablation probe. The catheter system may further comprise means of delivering cryogenic energy to the mechanical ablation probe, to a region of the catheter in close proximity to the mechanical ablation probe, and/or to another region of the catheter. The catheter may further comprise means of rotating and steering the mechanical ablation probe.
... |
| Ablative ultrasonic-cryogenic apparatus | 20080039745 | 20080214 |
| An ablative apparatus that can be used to treat atrial fibrillation and other cardiac arrhythmias by ablating cardiac tissue is disclosed. When the distal end of the apparatus reaches the tissue to be ablated, an ablation probe driven by a transducer is vibrated. Scratching the tissue with abrasive members, the vibrating ablation probe is capable of mechanically ablating tissues. This mechanical ablation may be utilized to penetrate epicardial fat, thereby exposing the underlying myocardium. The ablative apparatus may then be used subject the exposed myocardium to mechanical ablation, cryoablation, ultrasonic ablation, and/or any combination thereof.
... |
| Transmission line with heat transfer ability | 20080033424 | 20080207 |
| The present invention relates to systems and devices for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In particular, the present invention relates to systems and devices for the delivery of energy with heat transfer ability. In some embodiments, the systems and devices also have variable characteristic impedance as a result of the use of heat transfer materials. In certain embodiments, methods are provided for treating a tissue region (e.g., a tumor) through application of energy with the systems and devices of the present invention.
... |
| Post-operative control of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart | 20080004662 | 20080103 |
| To control cardiac arrhythmias such as atrial fibrillation post-operatively, various non-ablative agents include polymers, fibroblasts, neurotoxins, and growth factors are introduced into one or more cardiac fat pads into the atrioventricular nodal fat pad in proximity to the autonomic ganglia therein. Any desired technique may be used for introducing the agent, including injection. The sinoatrial nodal fat pad target site and the atrioventricular nodal fat pad target site are identified using a stimulator, which may have electrodes coupled thereto or which may coupled to electrodes built into a delivery system.
... |
| Tricyclic guanidine derivatives as sodium-proton exchange inhibitors | 20070299051 | 20071227 |
| are disclosed, wherein U is C(O), CRaRb, O, NRa or S(O)m; V is CRaRb or NRa; W is S(O)m; wherein Ra is H, alkyl, cycloalkyl, alkenyl or aralkyl; Rb is H, alkyl, OH, ORa or OCORa, and m is the integer 0, 1 or 2; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein with the proviso that at least one of R1, R2, R3, R4, R5, R6, R7 or R8 is guanidino or guanidino carbonyl. These derivatives are sodium-proton exchange inhibitors and are useful as medicaments for the treatment of, for example, organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy, hypertension, cell proliferative disorders and diabetes.
... |
| Kv1.5 potassium channel inhibitors | 20070299120 | 20071227 |
| The present invention relates to 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents. The present invention further relates to compositions comprising said Kv1.5 potassium channel inhibitors, and to methods for treating cardiac arrhythmia.
... |
| Protein activity modification | 20070293901 | 20071220 |
| A method of treating a cardiac arrhythmia, comprising: determining a desired arrhythmia control; selecting an electric field having an expected effect of modifying protein activity of at least one protein as a response of a cardiac tissue to the field, said expected effect correlated with said desired arrhythmia control; and applying said field to said cardiac tissue.
... |
| Energy delivery system and uses thereof | 20070288079 | 20071213 |
| The present invention relates to systems and devices for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In particular, the present invention relates to systems and devices for the delivery of energy with optimized characteristic impedance. In certain embodiments, methods are provided for treating a tissue region (e.g., a tumor) through application of energy with the systems and devices of the present invention.
... |
| Center fed dipole for use with tissue ablation systems, devices and methods | 20070282319 | 20071206 |
| The present invention relates to systems and devices for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In particular, the present invention relates to systems and devices for the delivery of energy employing a center fed dipole component. In certain embodiments, methods are provided for treating a tissue region (e.g., a tumor) through application of energy with the systems and devices of the present invention.
... |
| Implantable medical device with chemical sensor and related methods | 20070270674 | 20071122 |
| In an embodiment, the invention includes an implantable medical device with a pulse generator and a chemical sensor in communication with the pulse generator, the chemical sensor configured to detect an ion concentration in a bodily fluid. In an embodiment, the invention includes a method for providing cardiac arrhythmia therapy to a patient including sensing a physiological concentration of an analyte, communicating data regarding the physiological concentration of the analyte to an implanted pulse generator, and delivering therapy to the patient based in part on the physiological concentration of the ion. In an embodiment, the invention includes a method for monitoring diuretic therapy. In an embodiment, the invention includes a method for controlling delivery of an active agent into a human body. Other aspects and embodiments... |
| Implantable medical device with chemical sensor and related methods | 20070270675 | 20071122 |
| In an embodiment, the invention includes an implantable medical device with a pulse generator and a chemical sensor in communication with the pulse generator, the chemical sensor configured to detect an ion concentration in a bodily fluid. In an embodiment, the invention includes a method for providing cardiac arrhythmia therapy to a patient including sensing a physiological concentration of an analyte, communicating data regarding the physiological concentration of the analyte to an implanted pulse generator, and delivering therapy to the patient based in part on the physiological concentration of the ion. In an embodiment, the invention includes a method for monitoring diuretic therapy. In an embodiment, the invention includes a method for controlling delivery of an active agent into a human body. Other aspects and embodiments... |
| Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | 20070259864 | 20071108 |
| There is provided compounds of formula I, wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
... |
| Method and system for detecting cardiac arrhythmias during overdrive pacing | 20070255326 | 20071101 |
| A method and apparatus are provided for detecting cardiac arrhythmias during overdrive pacing. A maximum paced rate and a reduced paced rate for a heart are determined, the maximum paced rate being higher than the reduced paced rate. The heart is paced at the maximum paced rate. After the heart is paced at the maximum paced rate for a predetermined amount of time, the heart is paced at the reduced paced rate.
... |
| Method and system for detecting and treating junctional rhythms | 20070255328 | 20071101 |
| A method and an apparatus for treating cardiac arrhythmias are provided. An interval between first and second consecutive beats of a heart, having first and second chamber types, is determined. The heart is paced at a first rate if the first beat is from the first chamber type and the second beat is from the second chamber type and the interval is less than a predetermined amount of time or if the first and second beats are both from the second chamber type. The heart is paced at a second rate if the first beat is from the first chamber type and the second beat is from the second chamber type and the interval is more than the predetermined amount of time.
... |
| Tissue stabilization and ablation device | 20070244476 | 20071018 |
| Tissue stabilization and ablation devices and methods provide techniques for stabilizing and ablating body tissues during surgical ablation procedures. In many embodiments, for example, devices may be used in minimally invasive techniques for ablating epicardial tissue adjacent one or more pulmonary veins to treat atrial fibrillation. Tissue stabilization and ablation devices generally include a rigidifying bladder coupled with an ablation member. The devices may additionally include a tissue stabilizing bladder or means within the rigidifying bladder for enhancing tissue stabilization. The rigidifying bladder conforms to a tissue surface and then stiffens to help the device hold its shape and position and to stabilize the tissue. The ablation member is then used to ablate an area of tissue. Such cardiac stabilization and ablation devices and methods may... |
| Tissue stabilization and ablation methods | 20070244534 | 20071018 |
| Tissue stabilization and ablation devices and methods provide techniques for stabilizing and ablating body tissues during surgical ablation procedures. In many embodiments, for example, devices may be used in minimally invasive techniques for ablating epicardial tissue adjacent one or more pulmonary veins to treat atrial fibrillation. Tissue stabilization and ablation devices generally include a rigidifying bladder coupled with an ablation member. The devices may additionally include a tissue stabilizing bladder or means within the rigidifying bladder for enhancing tissue stabilization. The rigidifying bladder conforms to a tissue surface and then stiffens to help the device hold its shape and position and to stabilize the tissue. The ablation member is then used to ablate an area of tissue. Such cardiac stabilization and ablation devices and methods may... |
| Cardiac ablation devices and methods | 20070239155 | 20071011 |
| Devices and methods provide for ablation of cardiac tissue for treating cardiac arrhythmias such as atrial fibrillation. The devices and methods are used to ablate epicardial tissue in the vicinity of the pulmonary veins, and other locations on a heart. Devices generally include at least one tissue contacting member for contacting epicardial tissue and securing the ablation device to the epicardial tissue, and at least one ablation member for ablating the tissue. Various embodiments include features, such as suction apertures, which enable the device to attach to the epicardial surface with sufficient strength to allow the tissue to be stabilized via the device. For example, some embodiments may be used to stabilize a beating heart to enable a beating heart ablation procedure. Many of the devices... |
| Purine derivatives as a3 and a1 adenosine receptor agonists | 20070232626 | 20071004 |
| Disclosed are (N)-methanocarba adenine nucleosides of the formula: [Formula] as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. The invention also provides compounds that are agonists of both A1 and A3 adenosine receptors for use in cardioprotection.
... |
| Tissue stabilization and ablation devices and methods | 20070233226 | 20071004 |
| Tissue stabilization and ablation devices and methods provide techniques for stabilizing and ablating body tissues during surgical ablation procedures. In many embodiments, for example, devices may be used in minimally invasive techniques for ablating epicardial tissue adjacent one or more pulmonary veins to treat atrial fibrillation. Tissue stabilization and ablation devices generally include a rigidifying bladder coupled with an ablation member. The devices may additionally include a tissue stabilizing bladder or means within the rigidifying bladder for enhancing tissue stabilization. The rigidifying bladder conforms to a tissue surface and then stiffens to help the device hold its shape and position and to stabilize the tissue. The ablation member is then used to ablate an area of tissue. Such cardiac stabilization and ablation devices and methods may... |
| Methods of using hcn genes to treat cardiac arrhythmias | 20070218034 | 20070920 |
| The subject invention is directed to methods of treating cardiac pacing dysfunction by administering HCN genes, alone or in combination with other genes.
... |
| Method and apparatus for the guided ablative therapy of fast ventricular arrhythmia | 20070219452 | 20070920 |
| Method and apparatus for guiding ablative therapy of abnormal biological electrical excitation. The excitation from the previous excitatory wave is significant at the beginning of the next excitation. In particular, it is designed for treatment of fast cardiac arrhythmias. Electrical signals are acquired from recording electrodes, and an inverse dipole method is used to identify the site of origin of an arrhythmia. The location of the tip of an ablation catheter is similarly localized from signals acquired from the recording electrodes while electrical pacing energy is delivered to the tip of the catheter close to or in contact with the cardiac tissue. The catheter tip is then guided to the site of origin of the arrhythmia, and ablative radio frequency energy is delivered to its tip... |
| Devices and methods for creating continuous lesions | 20070219546 | 20070920 |
| The present invention discloses devices and methods for creating multiple lesions using ablation devices in anatomical regions such as the heart, for example to treat cardiac arrhythmias. The present invention discloses methods and devices to create continuous lesions using area ablation devices. The present invention discloses various embodiments of reference assemblies for accurately positioning ablation devices having ablating portions, especially deployable ablation portions adapted for area ablation. The ablation devices are positioned using the reference assemblies in the anatomy to create one or more lesions. The present invention also discloses several method embodiments for creating continuous lesions using deployable ablating portions to produce two or more overlapping lesions.
... |
| Detection of cardiac arrhythmias using a photoplethysmograph | 20070213624 | 20070913 |
| A method for diagnosis includes receiving from a sensor coupled to a body of a patient a photoplethysmograph signal, which is indicative of blood flow in the body. The photoplethysmograph signal is processed so as to identify at least one irregularity in a heart rhythm of the patient. A record indicating a time of occurrence of the at least one irregularity is made and processed so as to diagnose a pathological cardiac condition of the patient.
... |
| Methods of identifying and/or assessing cardiac arrhythmias using an implantable medical device | 20070179383 | 20070802 |
| Apparatus using one or more modes of statistical analysis with one or more monitored parameters of a patient's heart to identify and/or assess arrhythmias. Through use of the one or more modes of statistical analysis, a medical professional can be aided during evaluation of patient data for diagnosis of the patient. At least one of the monitored parameters may include one or more values used representatively for storage intervals of a selected length. As such, for each storage interval, a value may be determined for the one monitored parameter occurring at an upper percentile and a lower percentile. In addition, a median value may be determined for the one monitored parameter for each storage interval. Over a plurality of the storage intervals, these determined values can... |
| Malonamic acids and derivatives thereof as thyroid receptor ligands | 20070173548 | 20070726 |
| The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders.
... |
| Methods and apparatus employing ionizing radiation for treatment of cardiac arrhythmia | 20070173812 | 20070726 |
| Method and apparatus are disclosed employing ionizing radiation for forming lines of ablation or lesions in cardiac tissue to treat atrial fibrillation or other electrophysiological problems with the heart. The apparatus may include a catheter in which the radiation source is advanced hydraulically after the catheter is in place within the heart. Various fixation devices are also disclosed for fixing the location of the catheter within the heart.
... |
| Ablative treatment of the heart to improve patient outcomes following surgery | 20070156185 | 20070705 |
| Devices and methods provide for ablation of cardiac tissue for treating cardiac arrhythmias such as atrial fibrillation. Although the devices and methods are often be used to ablate epicardial tissue in the vicinity of at least one pulmonary vein, various embodiments may be used to ablate other cardiac tissues in other locations on a heart. Devices generally include at least one tissue contacting member for contacting epicardial tissue and securing the ablation device to the epicardial tissue, and at least one ablation member for ablating the tissue. Various embodiments include features, such as suction apertures, which enable the device to attach to the epicardial surface with sufficient strength to allow the tissue to be stabilized via the device. For example, some embodiments may be used to... |
| Discriminating polymorphic and monomorphic cardiac rhythms using template generation | 20070142736 | 20070621 |
| Cardiac arrhythmias are classified based on the morphology of the arrhythmia episode beats. Templates are formed using morphological features of the cardiac beats of the episode. The arrhythmia episode is classified as a monomorphic tachyarrhythmia or polymorphic tachyarrhythmia based on the one or more templates. The arrhythmia episode may be classified based on a number templates formed from the arrhythmia episode. The templates are formed by determining a measure of similarity between morphological features of a cardiac beat to a template. The similarities can be determined based on a pairing rule that determines which beat morphologies are compared. Selection of therapy for treating the arrhythmia episode may depend on the historical success of a therapy at mitigating previous arrhythmias of the same type as the arrhythmia... |
| Pharmaceutical compounds | 20070134155 | 20070614 |
| The invention comprises pharmaceuticals of formula (I) Z-(L)n-V, wherein V denotes a peptide, L denotes an optional linker, Z denotes a group that optionally can carry an imaging moiety M, n denotes 0 or 1. The pharmaceuticals are active as therapeutic agents for the treatment of heart failure, cardiac arrhythmias and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis and are also useful as diagnostic agents for the diagnosis of heart failure and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis.
... |
| Method of drug therapy in treatment of cardiac arrhythmias | 20070129447 | 20070607 |
| A method for treatment of cardiac arrhythmias is disclosed. The method comprises the combining of a sodium channel blocking medication and a potassium channel blocking medication into a therapeutic dosage and the delivery of the therapeutic dosage to a patient in treatment of a heart rhythm problem. The heart rhythm problems being treated include atrial fibrillation and atrial or ventricular tachycardia. Preferably, the therapeutic dosage is at least one tablet and the concentration of each medication is determined based upon the heart problem being treated, the underlying heart rate, the QT interval and other comorbid conditions of the patient. A pharmaceutical composition for the therapeutic treatment of cardiac arrhythmias in a patient is also provided having a combination of a sodium channel blocking medication and a... |
| Method and apparatus for preventing cardiac arrhythmias with endovascular stimulation | 20070129763 | 20070607 |
| Certain cardiac arrhythmias can be prevented by appropriate electrical stimulation of autonomic nerves innervating the heart. An implantable cardiac rhythm management device is configured to deliver such stimulation when an autonomic imbalance is predicted to be present via an endovascular electrode. Autonomic imbalance may be predicted to be present based upon circadian rhythms, detected heart rates, or detected heart rate variability.
... |
| Inhalation drug combinations | 20070122351 | 20070531 |
| A method for treating respiratory disorders by administrating by inhalation an effective amount of a β2-receptor agonist, an acceptable amount of a corticosteriod, and HFA 134a, to a patient in need thereof, is disclosed. Preferably, the β2-receptor agonist is salmeterol or a physiologically acceptable salt thereof, and the corticosteriod is fluticasone propionate or a solvate thereof. The combination of salmeterol, fluticasone proprionate, and HFA 134a may lower the risk of cardiac arrhythmias, sudden death, or hypercorticism that are sometimes associated with the simultaneous administration of a β2-receptor agonist and an anti-inflammatory corticosteroid.
... |
| Inhalation drug combinations | 20070122352 | 20070531 |
| A method for treating respiratory disorders by administrating by inhalation an effective amount of a β2-receptor agonist, an acceptable amount of a corticosteroid, and HFA 134a, to a patient in need thereof, is disclosed. Preferably, the β2-receptor agonist is salmeterol or a physiologically acceptable salt thereof, and the corticosteroid is fluticasone propionate or a solvate thereor. The combination of salmeterol, fluticasone proprionate, and HFA 134a may lower the risk of cardiac arrhythmias, sudden death, or hypercorticism that are sometimes associated with the simultaneous administration of a β2-receptor agonist and an anti-inflammatory corticosteroid.
... |
| Methods for the prediction of arrhythmias and prevention of sudden cardiac death | 20070123945 | 20070531 |
| Methods and kits are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart. The methods and kits comprise measuring serum NGF levels in a subject and detecting increases in NGF levels over baseline. The methods may further comprise initiating preventive therapy in response to a detected increase in serum NGF levels.
... |
| Isoquinolinone potassium channel inhibitors | 20060281743 | 20061214 |
| The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
... |
| Erg channel openers for the treatment of cardiac arrhythmias | 20060281794 | 20061214 |
| This invention relates to the use of ERG channel openers for the treatment of cardiac arrhythmias, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.
... |
| Method and apparatus for rate-dependent morphology-based cardiac arrhythmia classification | 20060281998 | 20061214 |
| An implantable medical device includes a tachyarrhythmia detection and classification system that classifies tachyarrhythmias based on a morphological analysis of template and arrhythmic waveforms. The morphological analysis takes effect of heart rate on the morphological characteristics of the template and arrhythmic waveforms into consideration. Correlation between morphological features of the template waveform and corresponding morphological features of an arrhythmic waveform provides for the basis for classifying the tachyarrhythmia. In one embodiment, corresponding morphological features are extracted from the template and arrhythmic waveforms at locations determined by the heart rate associated with a detected arrhythmia episode. In another embodiment, weighting factors each being a function of the heart rate are applied to the template and arrhythmic morphological features before a correlation coefficient is calculated.
... |
| Method and apparatus for cardiac arrhythmia classification using sample entropy | 20060281999 | 20061214 |
| An implantable medical device includes an arrhythmia detection and classification system that classifies an arrhythmia episode based on an irregularity parameter and/or a complexity parameter. The arrhythmia episode is detected from a cardiac signal. The irregularity parameter is indicative of the degree of cycle length irregularity of the cardiac signal and the complexity parameter is indicative of the degree of morphological complexity of the cardiac signal. One example of the irregularity parameter is an irregularity sample entropy, or a parameter related to the irregularity sample entropy, computed to indicate the cycle length irregularity. One example of the complexity parameter is a complexity sample entropy, or a parameter related to the complexity sample entropy, computed to indicate the morphological complexity. In one embodiment, the detected arrhythmia episode... |
| Apparatus and method for cardioversion | 20060282124 | 20061214 |
| The present invention is a system for terminating cardiac arrhythmia using existing defibrillators found in the field in conjunction with a safe junction box. The system is designed to allow the defibrillator to connect to specially designed catheters equipped with specially designed electrodes and external electrodes for coupling energy to the heart that is greatly less than that used with external defibrillation alone. The system has the ability to create internal cardioversion vectors and also “hybrid” cardioversion vectors by allowing the external and internal electrodes to act together in the cardioversion process that is used to terminate arrhythmia in temporary and quasi-permanent implant applications. The quasi-permanent implant applications are greater than thirty day but less than twelve month applications where an implanted defibrillator may not be... |
| Isoquinoline potassium channel inhibitors | 20060276450 | 20061207 |
| The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
... |
| Novel compounds for treatment of cardiac arrhythmia and methods of use | 20060276535 | 20061207 |
| The subject invention provides novel compounds for treatment of cardiac arrhythmia and methods of use.
... |
| Methanocarba cycloalkyl nucleoside analogues | 20060270629 | 20061130 |
| The present invention provides novel nucleoside and nucleotide derivatives that are useful agonist or antagonists of P1 and P2 receptors. For example, the present invention provides a compound of formula A-M, wherein A is modified adenine or uracil and M is a constrained cycloalkyl group. The adenine or uracil is bonded to the constrained cycloalkyl group. The compounds of the present invention are useful in the treatment or prevention of various diseases including airway diseases (through A2B, A3, P2Y2 receptors), cancer (through A3, P2 receptors), cardiac arrhythmias (through A1 receptors), cardiac ischemia (through A1, A3 receptors), epilepsy (through A1, P2X receptors), and Huntington's Disease (through A2A receptors).
... |
| Isoquinolinone potassium channel inhibitors | 20060270704 | 20061130 |
| The present invention relates to compounds having the structure formula (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
... |
| Arrhythmia discrimination using electrocardiograms sensed from multiple implanted electrodes | 20060253044 | 20061109 |
| Cardiac monitoring and/or stimulation methods and systems provide for monitoring, diagnosing, defibrillation and pacing therapies, or a combination of these capabilities, including cardiac systems incorporating or cooperating with neuro-stimulating devices, drug pumps, or other therapies. Embodiments of the present invention relate generally to implantable medical devices employing automated cardiac activation sequence monitoring and/or tracking for arrhythmia discrimination. Embodiments of the invention are directed to devices and methods involving sensing a plurality of composite cardiac signals using a plurality of implantable electrodes. A source separation is performed using the sensed plurality of composite cardiac signals and the separation produces one or more cardiac signal vectors associated with one or more cardiac activation sequences that is indicative of ischemia. A change of the one or more cardiac signal... |
| Structural carotenoid analogs for the inhibition and amelioration of disease | 20060229446 | 20061012 |
| A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid structural analog, either alone or in combination with another carotenoid analog, or co-antioxidant formulation. The analog or analog combination is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of ischemia-reperfusion injury. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of liver disease. The analog or analog combination may be administered to a subject for the... |
| Cardiac contractility modulation device having anti-arrhythmic capabilities and method of operating thereof | 20060212079 | 20060921 |
| A cardiac contractility modulating (CCM) device (30) includes an anti-arrhythmic therapy unit (38) for detecting a cardiac arrhythmia in a heart (2) of a patient based on processing electrical signals related to cardiac activity sensed at the heart, and for delivering anti-arrhythmic therapy to the heart. The device includes a cardiac contractility modulating (CCM) unit (40) capable of delivering cardiac contractility modulating (CCM) signals to the heart for modulating the contractility of a portion of the heart. The device may provide to the anti-arrhythmic therapy unit control signals associated with the delivery of the CCM signals to the heart. The control signals may be used to prevent interference of the CCM signals with the detecting of the cardiac arrhythmia. The device (30) includes a power source.... |
| Methods and systems for gated or pulsed application of ablative energy in the treatment of cardiac disorders | 20060200118 | 20060907 |
| The present invention comprises methods and systems for treating a cardiac arrhythmia in a mammal by administering gated or pulsed radiofrequency current or other ablative energy to the mammal during one or more time periods of increased coronary blood flow. Preferred embodiments of the invention comprise, without limitation, the gated or pulsed administration of radiofrequency current in association with the formation of the dicrotic notch in the arterial blood pressure curve of the mammal. In accordance with the invention, the thermal effects of ablative energy application on the coronary artery are avoided or mitigated due to rapid coronary blood flow resulting in heat loss and minimization of damage to blood vessels.
... |
| Non-invasive measurement of suprasystolic signals | 20060178585 | 20060810 |
| An apparatus for assessing cardiovascular status of a mammal comprises a system for locally applying a pressure to an artery capable of restricting blood flow through said artery, a wideband external pulse transducer having an output and situated to measure suprasystolic signals proximate to said artery, and a computing device receiving said output for calculating vascular compliance values. The method described is particularly useful for determining cardiac output, assessing whether a pregnant female has preeclampsia or a patient has cardiac insufficiency, or assessing cardiac arrhythmia.
... |
| New oxabispidine compounds useful in the treatment of cardiac arrhythmias | 20060166979 | 20060727 |
| wherein R1, R2, R3, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
... |
| New oxabispidine compounds useful in the treatment of cardiac arrhythmias | 20060166980 | 20060727 |
| wherein R1, R2, R3, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
... |
| Algorithms for detecting cardiac arrhythmia and methods and apparatuses utilizing the algorithms | 20060167364 | 20060727 |
| A method for detecting a cardiac arrhythmia from an electrocardiogram includes the steps of identifying a plurality of R-waves in the electrocardiogram during a predetermined time interval; extracting heartbeat complexes corresponding to the identified R-waves; identifying a key region within each heartbeat complex that is morphologically altered in the event of the cardiac arrhythmia; calculating a statistical measurement of an ensemble of the key regions from each of the heartbeat complexes; and determining from the statistical measurement whether the cardiac arrhythmia occurred during the predetermined time interval. An apparatus is also provided that includes a processor that is coupled to receive an electrocardiogram, and is configured in response thereof to perform the method for detecting a cardiac arrhythmia.
... |
| Methods and apparatuses for cardiac arrhythmia classification using morphology stability | 20060161069 | 20060720 |
| An implantable cardioverter/defibrillator (ICD) includes a tachyarrhythmia detection and classification system that classifies tachyarrhythmias based on a morphological analysis of arrhythmic waveforms and a template waveform. Correlation coefficients each computed between morphological features of an arrhythmic waveform and morphological features of the template waveform provide for the basis for classifying the tachyarrhythmia. In one embodiment, morphological features are collected from a sensed arrhythmic waveform, and temporally corresponding morphological features are extracted a stored template waveform. In one embodiment, a correlation analysis takes into account the uncertainty associated with the production of the template waveform by using a template band that includes confidence intervals. In one embodiment, a correlation analysis produces Mahalanobis distance-based correlation coefficients for use in the classification of the tachyarrhythmia. In one embodiment, the... |
| Method for low-voltage termination of cardiac arrhythmias by effectively unpinning anatomical reentries | 20060161206 | 20060720 |
| A method for extinguishing a cardiac arrhythmia utilizes destructive interference of the passing of the reentry wave tip of an anatomical reentry through a depolarized region created by a relatively low voltage electric field in such a way as to effectively unpin the anatomical reentry. Preferably, the relatively low voltage electric field is defined by at least one unpinning shock(s) that are lower than an expected lower limit of vulnerability as established, for example, by a defibrillation threshold test. By understanding the physics of the electric field distribution between cardiac cells, the method permits the delivery of an electric field sufficient to unpin the core of the anatomical reentry, whether the precise or estimated location of the reentry is known or unknown and without the risk... |
| Ultrasound triggering method | 20060155192 | 20060713 |
| The invention relates to a triggered ultrasound imaging method for imaging of the myocardium, minimizing the risk of eliciting cardiac arrhythmia. Particularly, the invention is directed to a method of assessing cardiac perfusion. Destruction pulses are triggered such that they fall within the refractory period of the heart, while imaging pulses are triggered at any given time of the ECG cycle, preferably during end-systole.
... |
| Epicardial ablation using focused ultrasound | 20060155269 | 20060713 |
| Apparatus for treating cardiac arrhythmias includes an ultrasonic ablation device incorporating an ultrasonic emitter (22, 400), means (10, 14, 402, 404) for positioning the ablation device outside of the heart but adjacent the epicardial surface of the heart, and means (26, 28, 30) for focusing the ultrasonic energy emitted by the emitter into an ablation region, so that the ablation region is disposed within the wall of the heart.
... |
| Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists | 20060147450 | 20060706 |
| This invention relates to the field of cardiac disease. More specifically, the invention relates to methods using an NGF antagonist for treating and preventing cardiac arrhythmia and methods of preventing death due to cardiac arrhythmia.
... |
| Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | 20060148880 | 20060706 |
| in which R1 to R6 have the meanings stated in the claims. The inventive compounds are suitable as antiarrhythmic medicaments with a cardioprotective component for infarction prophylaxis and infarction treatment and for the treatment of angina pectoris. They also inhibit in a preventive manner the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias and of heart failure.
... |
| Ablation catheter assembly having a virtual electrode comprising portholes | 20060111708 | 20060525 |
| An ablation catheter having a catheter shaft and a virtual electrode, the virtual electrode comprising portholes through an outer peripheral wall of the catheter shaft and a metal electrode, the catheter being used for treatment of cardiac arrhythmia, for example, atrial fibrillation, by electrically isolating a vessel, such as a pulmonary vein, from a chamber, such as the left atrium. The catheter shaft includes a proximal portion and a distal portion. The distal portion includes an active region, which is either a looped structure transverse to the longitudinal axis of the catheter shaft, or a linear structure that extends parallel to the longitudinal axis of the catheter shaft. During use, the active region is directed into contact with, for example, the wall of a pulmonary vein.... |
| Ablation system with feedback | 20060106375 | 20060518 |
| Devices, systems and methods are disclosed for the ablation of tissue and treatment of cardiac arrhythmia. An ablation system includes an ablation catheter that has an array of ablation elements and a location element, an esophageal probe also including a location element, and an interface unit that provides energy to the ablation catheter. The distance between the location elements, determined by calculating means of the system, can be used by the system to set or modify one or more system parameters.
... |
| System and method for magnetic-resonance-guided electrophysiologic and ablation procedures | 20060100506 | 20060511 |
| A system and method for using magnetic resonance imaging to increase the accuracy of electrophysiologic procedures includes an invasive combined electrophysiology and imaging antenna catheter which includes an RF antenna for receiving magnetic resonance signals and diagnostic electrodes for receiving electrical potentials. The combined electrophysiology and imaging antenna catheter is used in combination with a magnetic resonance imaging scanner to guide and provide visualization during electrophysiologic diagnostic or therapeutic procedures, such as ablation of cardiac arrhythmias. The combined electrophysiology and imaging antenna catheter may further include an ablation tip, and be used as an intracardiac device to deliver energy to selected areas of tissue and visualize the resulting ablation lesions. The antenna utilized in the combined electrophysiology and imaging catheter for receiving MR signals is preferably... |
| Method for treating cardiac muscle disorders | 20060083757 | 20060420 |
| Methods for treating cardiac muscle disorders, such as cardiac arrhythmias, by administration of a neurotoxin to cardiac muscle are disclosed. Bradycardia can be alleviated for several months by a single intrapericardial or intracardiac injection or infusion of a botulinum toxin. Tachycardia can be alleviated by preganglionic sympathetic nervous system administration of a botulinum toxin.
... |
| Endovascular catheter and method of use | 20060084969 | 20060420 |
| An electrosurgical medical device and method for treating cardiac arrhythmias. In one embodiment, an elongate catheter has a distal shaft end or balloon that carries an electrosurgical energy delivery surface comprising at least one electrode with a positive temperature coefficient of resistance (PTCR) surface and/or an electrode with a pressure sensitive variable resistance to provide a smart surface for controlling Rf current flow at the interface of electrosurgical surface and the tissue. The electrosurgical surface then can limit or modulate Rf energy delivery through the surface in response to the temperature of the tissue or the engagement pressure of the surface against the engaged tissue. In operation, the smart electrosurgical surface can prevent arcing at the electrode-tissue interface, and thus control ohmic heating to prevent tissue... |
| Camkii/calcium channel binding-related compositions and methods | 20060079445 | 20060413 |
| This invention provides a method for determining whether an agent inhibits binding between CaMKII and a Ca+2 channel. Furthermore, this invention provides a method for inhibiting binding between CaMKII and a Ca+2 channel in a cell. Finally, this invention provides methods of treating cardiac arrhythmia and neurological disorders.
... |
| Arrhythmia classification and therapy selection | 20060074331 | 20060406 |
| Different types of cardiac arrhythmia are classified based on the morphology of the arrhythmic beats. Cardiac beats associated with an arrhythmic episode are compared to a plurality of representative beat morphologies, each representative beat morphology characterizing a type of arrhythmia of the heart. An arrhythmic episode may be classified as a particular type of arrhythmia if the morphology of the arrhythmic cardiac beats matches a representative beat morphology characterizing the particular type of arrhythmia. An appropriate therapy for the particular type of arrhythmia may be selected based on the arrhythmia classification. A particular type of arrhythmia may be associated with one or more therapies used to treat the arrhythmia. The therapy used to treat the arrhythmia may comprise a therapy identified as a previously successful therapy.
... |
